Last reviewed · How we verify
NCT03221049
Radiomics for Diagnosing Liver Diseases and Evaluating Progression
trial testing radiomics in Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation in 3,000 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Third Affiliated Hospital, Sun Yat-Sen University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 3,000 |
| Start date | 1 January 2011 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- radiomics
Conditions studied
- Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation — all drugs for Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation →
Sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Who can join
Eligibility, any sex, with Hepatitis B / Liver Space-occupying Lesions / Patients After Ablation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Liver diseases are worldwide problems. liver fibrosis and hepatocellular carcinoma are mostly concerned by clinicians. Radiomcis can improve diagnosis accuracy and evaluate disease progression. Hence,investors try to combine radiomics and ultrasound images together in order to improve diagnosis performances of liver fibrosis, benign and malignant tumor and progression after liver ablations.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Bridging the Gap Between Imaging and Molecular Characterization: Current Understanding of Radiomics and Radiogenomics in Hepatocellular Carcinoma.
Ren L, Chen DB, Yan X, She S, et al · · 2024 · cited 2× · PMID 39619602 · DOI 10.2147/jhc.s423549
Verify or expand the search:
- PubMed search for NCT03221049
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of radiomics
Trials testing the same drug.
- NCT06167863 — Retrospective Analysis of the Correlation Between Imaging Features and Pathology, Prognosis in Renal Tumors · completed
- NCT05400304 — Radiomics Combined With Frozen Section Prediction Model for Spread Through Air Space in Lung Adenocarcinoma · unknown
- NCT05387460 — Radiomics Based Multimodal Transvaginal Ultrasound Imaging in Endometrial Cancer · unknown
- NCT04955522 — Multimodal Imaging Analysis of Spinal Tumors · completed
- NCT03872362 — Radiomics Multifactorial Biomarker for Pulmonary Nodules · completed
Other Third Affiliated Hospital, Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07409259 — PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure · EARLY_PHASE1 · active not recruiting
- NCT07281664 — Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hep · NA · not yet recruiting
- NCT07338552 — Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China · NA · not yet recruiting
- NCT07354997 — Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients · NA · completed
- NCT07253233 — Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03221049 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Third Affiliated Hospital, Sun Yat-Sen University
- Last refreshed: 2 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03221049.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing